Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | PDE2A | O00408 | 10/20 | 0.32 |
| ▸ | HTR1D | P28221 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.30 |
| ▸ | CDK9 | P50750 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14413457 | 0.87 | PDE10A (0.42) | PDE2AHTR1DHTR3AHTR6TMEM97 | |
| SCHEMBL14545810 | 0.82 | DRD3 (0.32) | DRD3PDE2AHTR1DHTR3AHTR6 | |
| SCHEMBL14413451 | 0.78 | HTR1D (0.31) | HTR1DHTR3AHTR6TMEM97HTR1A | |
| SCHEMBL14050853 | 0.76 | MALT1 (0.43) | PDE2A | |
| SCHEMBL14413470 | 0.70 | GSK3B (0.33) | PDE2A | |
| SCHEMBL14545219 | 0.70 | CHEK1 (0.39) | HTR1DHTR3AHTR6TMEM97HTR1A | |
| SCHEMBL14413493 | 0.69 | CHEK1 (0.32) | — | |
| SCHEMBL14545797 | 0.68 | PDE10A (0.47) | HTR1DHTR3AHTR6TMEM97HTR1A | |
| SCHEMBL14050787 | 0.67 | MALT1 (0.45) | PDE2A | |
| SCHEMBL14413582 | 0.66 | CHEK1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | DRD3 4294/4885PDE2A 1219/4885HTR1D 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.